Form 4: Amgen SVP Sells Shares Under 10b5-1 Plan

Amgen's SVP of Business Development, Rachna Khosla, sold 890 shares of common stock for approximately $336.24 per share under a pre-arranged trading plan.

Summary

• Rachna Khosla, Senior Vice President of Business Development at Amgen Inc., reported a sale of common stock.
• The transaction involved the disposition of 890 shares of Amgen common stock.
• The shares were sold at an average price of $336.2422 per share, with prices ranging from $336.2219 to $336.30.
• The transaction occurred on November 12, 2025, and was filed on November 13, 2025.
• Following the transaction, Rachna Khosla beneficially owns 7,082 shares, which include 93 Dividend Equivalents (DEs).
• The sale was executed pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: A routine insider sale under a 10b5-1 plan is generally considered neutral. It reflects personal financial planning rather than a direct statement on company performance or outlook.

Future Outlook

N/A. This filing reports a past transaction and does not provide forward-looking statements or guidance.

Industry Context

N/A. This is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Minimal direct impact on shareholders, as it represents a routine, pre-planned sale by a single executive. The sale of 890 shares is a small fraction of the company's total outstanding shares.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Stock Sale, Rachna Khosla, SVP Business Development, 10b5-1 Plan